Oral Peptides in Research: Formats, Bioavailability, and What’s Actually Sold in Canada

Last reviewed: September 2026

“Oral peptides,” “peptide pills” and “BPC-157 capsules” are among the most-searched format questions in Canada, and almost every page answering them is selling a capsule. This guide answers the question underneath: why research peptides are sold as lyophilised powder in vials, what the peer-reviewed literature actually reports about oral bioavailability, why BPC-157 is the one compound where oral administration has a real research history, and what the difference is between a supplement-market “peptide pill” and a research material with a Certificate of Analysis. Quantum sells lyophilised vials only. That is not a limitation we apologise for — it is the format the research standard requires, and the rest of this page explains why.

Why research peptides come as lyophilised vials, not pills

A peptide is a short chain of amino acids held together by peptide bonds, and the digestive system is, in the most literal sense, a machine for breaking peptide bonds. Three things happen to a peptide that is swallowed. Stomach acid begins to denature it. Proteases in the stomach and small intestine — pepsin, trypsin, chymotrypsin and the brush-border peptidases — cleave it into fragments and free amino acids. Whatever survives must then cross the intestinal epithelium, which is a tight barrier that admits small, lipophilic molecules readily and large, polar, hydrogen-bonding molecules like peptides very poorly. The result is that, for most peptides, oral administration delivers a small fraction of a percent of the material intact into circulation, and the fraction varies unpredictably.

Lyophilisation — freeze-drying — sidesteps all of that for the research setting. Removing the water from a purified peptide solution under vacuum leaves a stable powder in which the peptide bonds are not exposed to hydrolysis, oxidation or enzymatic attack. Sealed in a vial and kept cold and dark, lyophilised material holds its identity and purity for an extended period, and it can be reconstituted in the laboratory to an exact concentration with bacteriostatic water. That is why an independent laboratory can test a lyophilised vial by HPLC and mass spectrometry and issue a batch-specific Certificate of Analysis for it: the material in the vial is a defined, stable, measurable quantity of a defined molecule. A capsule of peptide mixed with excipients is none of those things.

Oral bioavailability: what the published literature shows

Oral bioavailability is the fraction of an administered dose that reaches systemic circulation intact. For small-molecule drugs it is often high. For peptides it is, with rare exceptions, very low: reviews of oral peptide delivery consistently report that unmodified peptides achieve oral bioavailabilities below one to two percent, and frequently well below one percent, in the animal models in which they are measured. The reasons are the ones above — enzymatic degradation and poor epithelial permeability — and they are structural properties of the peptide class rather than problems that a better capsule fixes.

The instructive exception is pharmaceutical, not research-market. Oral semaglutide, marketed in Canada as the Health-Canada-authorized prescription drug Rybelsus, achieves oral delivery only by co-formulating the peptide with an absorption enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, or SNAC) that locally raises gastric pH and increases transcellular uptake — and even then the absolute bioavailability is on the order of one percent, which is why the tablet contains a far larger quantity of peptide than the corresponding injection. It took a decade of formulation science to get one peptide across the gut wall in a reproducible way, and the product that resulted is an authorized drug with a DIN, not a research chemical. If you want the wider context on that molecule class, see our GLP-1 research peptides guide.

The honest summary for a researcher is that “oral peptide” is not a format that research suppliers can offer with a straight face. There is no way to put a lyophilised research peptide into a capsule and claim anything defensible about what fraction of it survives, because for almost every compound in the catalogue nobody has measured it, and for the few where somebody has, the answer is a small number with a wide error bar.

BPC-157 and oral administration in research

BPC-157 is the reason this page cannot simply say “peptides are not oral.” It is a synthetic fifteen-amino-acid fragment of a protein found in human gastric juice, and that origin gives it an unusual property in the published literature.

Gastric-stability findings — why BPC-157 is the unusual case

The characteristic that sets BPC-157 apart is reported stability in gastric juice: in vitro, the peptide has been described as remaining intact in human gastric juice for more than 24 hours, where most peptides are degraded within minutes. That stability is why a substantial share of the preclinical BPC-157 literature — much of it from a single research group in Zagreb — uses oral (per-oral, in drinking water or by gavage) administration in rodent models alongside intraperitoneal and intragastric routes. It is a genuine point of difference from TB-500, GHK-Cu or the growth-hormone secretagogues, none of which have a comparable oral research history. It is also, importantly, a statement about stability in the stomach, not a measured systemic bioavailability figure: surviving gastric juice in a test tube and reaching circulation intact in an animal are different questions, and the literature is much clearer on the first than the second.

Route comparisons in published studies

Where the rodent literature compares routes, it generally reports that BPC-157 produced measurable effects in the models studied whether given orally or parenterally, with the oral quantities used in those models typically higher than the parenteral ones. What the literature does not contain is a human pharmacokinetic study establishing oral bioavailability, a human route-comparison trial, or any human efficacy data for either route. Those are the findings, stated as findings in animal models, and they are as far as an honest page can go. Anyone telling you which route “works better” is answering a question the published evidence has not asked. Quantum supplies BPC-157 as a lyophilised research peptide, batch-tested, in a vial; we do not sell BPC-157 capsules and do not intend to.

TB-500 and other compounds: why oral formats are rare

TB-500 — the synthetic fragment of thymosin beta-4 — has no meaningful oral research literature. It is a 43-amino-acid peptide with none of BPC-157’s gastric stability, and the preclinical work on it is almost entirely parenteral. The same is true of GHK-Cu, the growth-hormone secretagogues (CJC-1295, ipamorelin, tesamorelin), the melanocortin analogues, and the neuropeptides Selank and Semax, which in their research history are intranasal or injectable, never oral. When a vendor lists “oral TB-500,” there is no study behind the format; there is a capsule-filling machine. TB-500 is supplied by Quantum, like everything else, as a lyophilised vial with its batch Certificate of Analysis.

“Peptide pills” on the consumer market vs. research standards

That leaves two categories of product on the Canadian market that both get called “oral peptides.” The first is the supplement-style capsule: a peptide (or something labelled as one) blended with fillers, sold with wellness claims, and typically accompanied by no batch-specific testing at all — you cannot run HPLC on a capsule and get a clean answer about the peptide inside it, and most sellers do not try. The second is a research material: a lyophilised peptide in a sealed vial, labelled for research use only, with a third-party Certificate of Analysis tied to the batch number on the label reporting HPLC purity and mass-spectrometry identity. The two are not different strengths of the same thing. They are different things, and only one of them can be verified. How to read that certificate is covered on the Certificate of Analysis hub, and the legal framework research peptides sit in is explained on are peptides legal in Canada?

Formats available at Quantum Peptides

Every peptide Quantum stocks is supplied in one format: lyophilised powder in a sealed, batch-coded vial, tested per batch by Peptide Test Canada, with the report archived at a permanent URL on the lab results page. There are no capsules, tablets, sprays or pre-mixed solutions in the catalogue. The same reasoning applies to pre-mixed nasal sprays, covered in the peptide nasal sprays guide. Reconstitution belongs in the laboratory, using bacteriostatic water sold as a separate research consumable; the handling guide is at how to reconstitute and store peptides. Browse the current catalogue in the shop, or start with the peptide guide for the compound-by-compound reference.

Frequently asked questions

How do oral and injectable routes compare in peptide research?

In the published animal-model literature, most peptides show oral bioavailability below one to two percent because of enzymatic degradation and poor intestinal permeability, while parenteral routes deliver the material intact. BPC-157 is the exception with a real oral research history, owing to its reported stability in gastric juice, but even there the literature is rodent-model work without a human pharmacokinetic comparison. No human efficacy comparison between routes exists for any research peptide, and this page does not offer one.

Can you buy oral peptides in Canada?

There is no Health-Canada-authorized oral research peptide product. What is sold as “oral peptides” in Canada is either a supplement-style capsule with no batch-specific testing or, from research suppliers, lyophilised vials for laboratory use only. Quantum supplies the latter and does not sell capsules.

Why is BPC-157 unusual in oral-administration research?

BPC-157 is derived from a protein found in gastric juice and has been reported to remain intact in human gastric juice for more than 24 hours in vitro, where most peptides degrade within minutes. That stability is why a significant share of the preclinical literature administers it orally in rodent models. It is a finding about gastric stability, not a measured human bioavailability, and it does not extend to other research peptides.

What is the difference between peptide capsules and lyophilised peptide vials?

A lyophilised vial contains a defined quantity of a single freeze-dried peptide, stable until reconstituted, that an independent laboratory can test by HPLC and mass spectrometry and certify per batch. A capsule contains peptide mixed with excipients in a format that is harder to test, rarely comes with a lot-matched certificate, and exposes the peptide to moisture and degradation. Only the vial can be independently verified against a published Certificate of Analysis.

Why is there no dosing information on this page?

Because nothing on this page is for human or veterinary use. Research materials carry no dosing, and the “oral dose” questions this page attracts presume a use the products are not supplied for. Personal-health questions belong with a licensed physician, and questions about authorized medicines belong with a prescriber and pharmacist.

All products referenced on this page are supplied for laboratory research use only and are not for human or veterinary use. Literature statements summarise published preclinical findings and are not claims about any product. Regulatory statements reflect Health Canada’s Drug Product Database and public advisory as of September 2026. Page last reviewed September 2026.